Send the following on WhatsApp
Continue to Chathttps://forschung.kssg.ch/en/projects/451-a-phase-12a-dose-escalation-and-cohort-expansion-study-for-safety-tolerability-and-efficacy-of-bms-986156-administered-alone-and-in-combination-with-nivolumab-bms-936558-anti-pd-1-monoclonal-anti-body-in-advanced-solid-tumors